Side-by-side comparison of AI visibility scores, market position, and capabilities
Bengaluru/Boston robotic digital pathology with RoboTome (2x sectioning speed) and MorphoLens (100+ slides/hour); $5M Series A Nov 2025 Inflexor Ventures with 80+ patents and US/European lab deployments competing with Leica for histopathology automation.
Morphle Labs is a Bengaluru, India and Boston, Massachusetts-based robotic microscopy and digital pathology company — raising $5 million in Series A funding in November 2025 led by Inflexor Ventures — providing histopathology laboratories with AI-powered physical automation platforms that address the speed and throughput bottlenecks in cancer diagnostics workflows. With 80+ patents filed and products deployed in leading US and European laboratories, Morphle's 100-member team has developed two flagship platforms: RoboTome (a robotic microtome system that slices biopsy tissue blocks at 2x the speed of experienced histotechnologists) and MorphoLens (a high-throughput slide scanner that digitizes 100+ histology slides per hour for digital pathology review). Founded to "revolutionize cancer diagnostics with physical AI," Morphle expands manufacturing, regulatory clearances, and global presence with the Series A.
AI assistant by xAI (Elon Musk); Grok 3 topped reasoning benchmarks in Feb 2025; 1M+ paying subscribers in week one; real-time X post access; distributed via X Premium; xAI valued at $24B.
Grok is the AI assistant developed by xAI, Elon Musk's AI company founded in 2023, and distributed primarily through X (formerly Twitter). Grok launched in November 2023 as an X Premium perk, with the notable differentiator of real-time access to X posts and a less restricted, more direct conversational style. Grok 3, released in February 2025, achieved top scores on the AIME math reasoning benchmark and ARC-AGI test, briefly positioning xAI as a frontier model lab.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.